Completed PHASE2 INTERVENTIONAL NCT01446770

Evaluation of the Initial Safety and Efficacy of Keloid Lesions Treated With MF-4181

A Prospective, Randomized, Comparative Feasibility Study Evaluating the Initial Safety and Efficacy of Keloid Lesions Treated With MF-4181 Adjunctive to Surgical Scar Revision

Sponsor: Halscion, Inc.

Conditions Keloid

Interventions Hydrogel scaffold (MF-4181)

Updated 6 times since 2017 Last updated: Mar 12, 2012 Started: Nov 30, 2010 Primary completion: Dec 31, 2011 Completion: Dec 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01446770, this PHASE2 trial focuses on Keloid and remains completed. Sponsored by Halscion, Inc., it has been updated 6 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Halscion, Inc.

Data source: Halscion, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nassau, The Bahamas